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There was a reduction in the risk of a PONV event in the
post phase (OR  0.67, 95% CI 0.67 to 0.97, p  0.04).
The risk of PONV was significantly reduced with the ad-
ministration of prophylactic medications (OR  0.46,
95% CI 0.46 to 0.67). There was a reduction in the mean
number of PONV episodes in the post phase (1.81
events) versus the pre phase (1.47 events, p  0.02). A re-
duction in mean PONV management costs was observed
in the post phase ($8.31, SD 8.50) as compared to the
pre-phase ($10.23, SD 8.25, p  0.02). For mean pro-
phylactic costs, these were significantly higher in the
post-implementation phase when compared to the pre-
implementation phase ($1.64, SD 3.36 vs. $0.91, SD
2.43, p  0.013). Univariate sensitivity analyses revealed
that the economic results were sensitive to several param-
eters. CONCLUSION: The implementation of pre-printed
order forms for PONV prophylaxis and treatment appears
to be an effective and economically attractive strategy.
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OBJECTIVES: Whilst differences between Caucasian,
African and Asian menopausal women have been well
documented, the aim of this study is to explore the rela-
tionship between menopause, HRT use and aspects of
quality of life (QoL) across five European countries.
METHODS: A large-scale observational study of
women’s health in France, Germany, Italy, Poland, UK
was conducted with 7806 women, aged 45–65, and con-
sulting gynecologists or primary care physicians (n 
530). QoL was assessed with the Women’s Health Ques-
tionnaire (vasomotor, depressed mood and sexual behav-
ior scales). RESULTS: Mean age (range 52.5 to 54.7) and
time since menopause were similar across all countries.
Findings suggested differential use of HRT across Europe
(current or lapsed): high in Germany (68%), low in
France (50%) and Italy (49%) (chi-square  139, P 
0.001). We compared aspects of QoL between users and
non-users (stratified by time since menopause). Within 5
years of menopause HRT users experienced: significantly
fewer vasomotor symptoms than non-HRT users across
all countries (z  15,9 p  0.001); significantly less de-
pression (z  10.5, P  0.001) across all countries ex-
cept the UK, and significantly better sexual functioning in
Italy and Germany (z  7.6, p  0.001). For women
experiencing menopause over 5 years ago, HRT users
had better scores in sexual (z  12.2, P  0.001) and
mood (z  3.0, P  0.002) domains than non-users in
all countries, but no differences were observed for vaso-
motor symptoms. CONCLUSIONS: Within 5 years of
menopause, HRT improves those aspects of menopausal
symptoms which are most important to women at that
time in their lives (vasomotor symptoms, mood) irrespec-
tive of country. After 5 years, across countries, the im-
pact of vasomotor symptoms on women naturally de-
creases and thus HRT users no longer experience a
benefit over non-users. However, the benefits of HRT on
sexual functioning and mood continue. These findings
suggest that pooling European WHQ data may be appro-
priate.
NO SPECIFIC OR MULTIPLE
DISEASES-HEALTH POLICY
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OBJECTIVES: To analyse the impact of parallel trade of
pharmaceuticals on welfare and innovation in the long
run and to estimate the impact of costs for pharmaceuti-
cals in some therapeutic areas in the short run. METH-
ODS: Identify arguments for and against parallel trade by
use of literature review and by interviewing agens in-
volved in parallel trade of pharmaceuticals. Official data
of prices and sales of pharmaceuticals are used to esti-
mate the impact of parallel trade on the drug bill. RE-
SULTS: In Europe the principle of free trade and the
harmonization of registration requirements for pharma-
ceuticals tend to force price convergence across markets,
i.e. a uniform ‘Euro price’. Parallel trade have reduced
annual costs for pharmaceuticals for treating ulcer re-
lated diseases by about 19 percent and for the treatment
of inhaled steroids of about 8 percent in Sweden. These
cost savings are compared with the excess costs for the
distribution and storage of parallel-imported products.
Comparison shows net cost savings for the ulcer related
diseases and inhaled steroids in the short run. CONCLU-
SIONS: There is a conflict between the principle of free
trade and the principle of intellectual property rights
(e.g., patent, brand-names, etc.). The purpose of intellec-
tual property rights is to provide economic incentives for
the innovative industry to develop new medicines. New
medicines are products with relatively high R&D costs,
difficult to finance without patent protection and price
discrimination.
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OBJECTIVE: This study evaluated attitude of physicians
toward formularies as well as services provided by the
pharmacy department in a large independent practice as-
sociation (IPA). METHODS: Surveys (n  280) were
sent to all practitioners in the IPA. The survey requested
information on physician use of and satisfaction with the
existing printed formulary quick list, their satisfaction
with the pharmacy services, and their attitude towards
formularies in general using a five-point strongly agree-
strongly disagree scale. We received 90 completed sur-
veys with a response rate of 32%. RESULTS: Majority of
respondents were staff physicians (87%). Around 31%
indicated pediatrics as their specialization followed by
family medicine (17%) and internal medicine (17%).
Practitioners who indicated that they had received the
formulary quick list (37%) were highly satisfied (3.44 
0.84) with it. Practitioners were very satisfied with the
performance (4.27  0.79), interaction (4.35  0.81),
and services offered (4.21  0.79) by the pharmacies.
Their attitude towards pharmacist playing a more active
role in patient care was positive (3.54  0.98). However,
their attitude towards formularies in general was nega-
tive. They agreed that formularies increased the amount
of time spent making drug choices (4.01  1.1), limited
access to the best medicines for patients (3.63  0.88),
resulted in less-effective medicines (3.01  0.99), com-
promised the quality of drugs prescribed (3.36  0.92),
and reduced the opportunities to offer the best medica-
tion for patients (3.43  0.82). CONCLUSION: Physi-
cians had negative attitude towards formularies in gen-
eral. However, they were satisfied with the services
offered by pharmacists, and they were positive towards
more patient care involvement by the pharmacists. Physi-
cians were also satisfied with the formulary quick list of-
fered by the pharmacy department. A plan was developed
to provide practitioners with an interactive, intranet-




STRUCTURE, PROCESS, AND OUTCOMES
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The escalating demand for pharmacoeconomic research
has exceeded the supply of available researchers. Post-
graduate pharmacoeconomic fellowships emerged to
train and produce quality independent researchers to
meet these growing educational needs. However, even af-
ter more than ten years in existence, the effectiveness of
these programs has not been formally evaluated. In order
to determine their effectiveness, first, a set of measures
for pharmacoeconomic fellowship programs needs to be
developed. OBJECTIVE: To construct a framework to
examine the potential structure, process, and outcome
measures for pharmacoeconomic fellowship programs.
METHODS: Using the Donabedian model, we discuss
the structures, processes, and outcomes of pharmacoeco-
nomic fellowship programs. RESULTS: We begin by fo-
cusing on the structure of these programs, including facil-
ities, qualification of the teaching staff, and operations of
the institution. The types of settings involved in pharma-
coeconomic fellowships are illustrated, and the experi-
ence and skills of preceptors and fellowship applicants
are defined. The processes of pharmacoeconomic fellow-
ships are reviewed, and the different characteristics of
these programs such as the research and the educational
components are discussed. Potential outcome measures
of pharmacoeconomic fellowship programs are dis-
cussed. CONCLUSION: A framework for examining the
structure, process, and outcome measures for pharmaco-
economic fellowship programs is given. Measures evalu-
ating the outcomes of fellowship programs need to be de-
veloped. Further research is needed to determine the
effectiveness of pharmacoeconomic fellowship programs.
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Pharmaceutical benefit management (PBM) programs are
key to the provision of prescription drugs among those
enrolled in health plans. A recent survey of HMOs re-
vealed 600 of 604 HMOs had a drug benefit; and only 57
HMOs of the 600 with a drug benefit did not provide
prescription drug coverage through a PBM (PBMI, 2000).
Several proposals have advocated use of PBMs to admin-
ister outpatient prescription drug benefits for Medicare
enrollees. Thus, the demand for accountability and a
means to evaluate performance of PBM programs is
growing; yet a set of standardized indicators for evaluat-
ing PBM performance does not yet exist. OBJECTIVE:
Explore the array of functions performed by PBMs and
measures used to evaluate PBM performance. Recom-
mend additional measures that should be considered to-
ward development of a comprehensive measurement set
for evaluating PBM activities. METHODS: MEDLINE
and web searches were conducted to develop a summary
of PBM functions and existing PBM-related indicators.
Measures used in other performance measurement activi-
ties that could be modified to assess PBM performance
also were identified. RESULTS: PBM activities fall into
four major categories: (1) administrative and manage-
ment, (2) drug use control, (3) cost containment, and (4)
disease management. Monitoring costs and savings of us-
ing drug management programs is the main focus of PBM
performance measurement to date. Several entities have
participated in efforts to develop measures for evaluating
pharmaceutical care, but none has defined a comprehen-
sive set of performance measures. Additional measures
